NBIS vs LGND vs PRGO vs INVA vs TEVA

For growth investors, Nebius Group N.

V. (NBIS) is the stronger pick with 350. 9% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Nebius Group N. V. (NBIS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Nebius Group N. V. at 1679. 7x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Nebius Group N.

V. (NBIS) delivered a total return of +823. 9%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: NBIS returned +784. 6% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 11β versus Nebius Group N. V. 's 3. 04β — meaning NBIS is approximately 2570% more volatile than INVA relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nebius Group N.

V. (NBIS) is pulling ahead at 350. 9% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, NBIS leads at 239. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -112. 5% for NBIS. At the gross margin level — before operating expenses — LGND leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 24. 6x for Ligand Pharmaceuticals Incorporated — 19. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 208. 9% to $36. 20.

In this comparison, PRGO (9.

8% yield) pays a dividend. NBIS, LGND, INVA, TEVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 11)). Nebius Group N. V. (NBIS) carries a higher beta of 3. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +95. 6%, NBIS: +784. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NBIS (Communication Services) and LGND (Healthcare) and PRGO (Healthcare) and INVA (Healthcare) and TEVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NBIS is a mid-cap high-growth stock; LGND is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; INVA is a small-cap high-growth stock; TEVA is a mid-cap quality compounder stock. PRGO pays a dividend while NBIS, LGND, INVA, TEVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.